BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Tsingke Biotech and iGeneTech partner to lead synthetic biology advancements in China

March 10, 2026 | News

Synthetic biology is rapidly emerging as a transformative field with wide-reaching applications



Beijing Tsingke Biotech and iGeneTech Bioscience have announced a strategic partnership aimed at advancing the field of synthetic biology. This collaboration brings together the strengths of both companies to drive innovation, streamline product development, and expand market reach.

Synthetic biology is rapidly emerging as a transformative field with wide-reaching applications, including precision medicine, bio-breeding, and gene editing. At the core of these advancements are high-throughput and column-based synthesis, which Tsingke Biotech and iGeneTech aim to further develop.

Tsingke Biotech, a leader in gene synthesis, has developed a fully integrated industrial chain that spans raw materials, equipment, process design, AI, and digital technologies. Known for its scalability, standardisation, and stability, the company's cutting-edge technology includes column synthesis and an intelligent factory-driven production system that supports from small-scale laboratory production (2nmol) to large-scale industrial synthesis (12mmol).

On the other hand, iGeneTech contributes its proprietary Ignite 3.0 high-throughput synthesis platform. With its ability to process oligo pools ranging from 4k to 650k in size and achieve synthesis lengths up to 200nt with error rates as low as 0.2%, this platform addresses key challenges around throughput, speed, and cost.